Literature DB >> 24590548

Eudragit L/HPMCAS blend enteric-coated lansoprazole pellets: enhanced drug stability and oral bioavailability.

Yu Fang1, Guozheng Wang, Rong Zhang, Zhihua Liu, Zhenghua Liu, Xiaohui Wu, Deying Cao.   

Abstract

The objectives of the present work were to use blends of Eudragit L and hydroxypropyl methylcellulose acetate succinate (HPMCAS) as enteric film coatings for lansoprazole (LSP) pellets. The enteric-coated pellets were prepared with a fluid-bed coater. The influence of the blend ratio, type of plasticizer, plasticizer level, coating level, and curing conditions on gastric stability in vitro drug release and drug stability was evaluated. Furthermore, the bioavailability of the blend-coated pellets in beagle dogs was also performed. The blend-coated pellets exhibited significant improvement of gastric stability and drug stability compared to the pure polymer-coated pellets. Moreover, the AUC values of blend-coated pellets were greater than that of the pure polymer-coated pellets. It was concluded that the using blends of Eudragit L and HPMCAS as enteric film coatings for LSP pellets improved the drug stability and oral bioavailability.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24590548      PMCID: PMC4037478          DOI: 10.1208/s12249-013-0035-1

Source DB:  PubMed          Journal:  AAPS PharmSciTech        ISSN: 1530-9932            Impact factor:   3.246


  39 in total

1.  Bioequivalence evaluation of lansoprazole 30-mg capsules (Lanfast and Lanzor) in healthy volunteers.

Authors:  H A Dugger; J D Carlson; W Henderson; G R Erdmann; S M Alam; R Dham
Journal:  Eur J Pharm Biopharm       Date:  2001-03       Impact factor: 5.571

2.  Aqueous HPMCAS coatings: effects of formulation and processing parameters on drug release and mass transport mechanisms.

Authors:  Florence Siepmann; Juergen Siepmann; Mathias Walther; Ross MacRae; Roland Bodmeier
Journal:  Eur J Pharm Biopharm       Date:  2006-03-06       Impact factor: 5.571

3.  Gastric pH profiles of beagle dogs and their use as an alternative to human testing.

Authors:  M Akimoto; N Nagahata; A Furuya; K Fukushima; S Higuchi; T Suwa
Journal:  Eur J Pharm Biopharm       Date:  2000-03       Impact factor: 5.571

4.  Solid state interactions between the proton pump inhibitor omeprazole and various enteric coating polymers.

Authors:  A Stroyer; J W McGinity; C S Leopold
Journal:  J Pharm Sci       Date:  2006-06       Impact factor: 3.534

5.  In vitro evaluation of dissolution properties and degradation products of omeprazole in enteric-coated pellets.

Authors:  S Storpirtis; D Rodrigues
Journal:  Drug Dev Ind Pharm       Date:  1998-11       Impact factor: 3.225

6.  Kinetics of release from enteric-coated tablets.

Authors:  S S Ozturk; B O Palsson; B Donohoe; J B Dressman
Journal:  Pharm Res       Date:  1988-09       Impact factor: 4.200

7.  Blends of enteric and GIT-insoluble polymers used for film coating: physicochemical characterization and drug release patterns.

Authors:  F Lecomte; J Siepmann; M Walther; R J MacRae; R Bodmeier
Journal:  J Control Release       Date:  2003-05-20       Impact factor: 9.776

8.  Polymer blends used for the aqueous coating of solid dosage forms: importance of the type of plasticizer.

Authors:  F Lecomte; J Siepmann; M Walther; R J MacRae; R Bodmeier
Journal:  J Control Release       Date:  2004-09-14       Impact factor: 9.776

9.  Lansoprazole for the prevention of recurrences of ulcer complications from long-term low-dose aspirin use.

Authors:  Kam Chuen Lai; Shiu Kum Lam; Kent Man Chu; Benjamin C Y Wong; Wai Mo Hui; Wayne H C Hu; George K K Lau; Wai Man Wong; Man Fung Yuen; Annie O O Chan; Ching Lung Lai; John Wong
Journal:  N Engl J Med       Date:  2002-06-27       Impact factor: 91.245

Review 10.  The choice of proton pump inhibitor: does it matter?

Authors:  Per M Hellström; Sigurd Vitols
Journal:  Basic Clin Pharmacol Toxicol       Date:  2004-03       Impact factor: 4.080

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.